COVID-19 Public Health Response (Vaccinations) Amendment Order (No 3) 2022: revoked, at 11.59 pm on 26 September 2022, pursuant to clause 3(2) of the COVID-19 Public Health Response (Revocations) Order 2022 (SL 2022/254).

Note

The Parliamentary Counsel Office has made editorial and format changes to this version using the powers under subpart 2 of Part 3 of the Legislation Act 2019.

Note 4 at the end of this version provides a list of the amendments included in it.

This order is administered by the Ministry of Health.

This order is made by the Minister for COVID-19 Response under sections 11 and 15(1) of the COVID-19 Public Health Response Act 2020 in accordance with section 9 of that Act.

1	Title
2	Commencement
3	Principal order
4	Schedule 3 replaced
	Schedule Schedule 3 replaced
	Explanatory note
	Gazette Information
	Notes

Order

1 Title

This order is the COVID-19 Public Health Response (Vaccinations) Amendment Order (No 3) 2022.

2 Commencement

This order comes into force at 11.59 pm on 25 March 2022.

3 Principal order

This order amends the COVID-19 Public Health Response (Vaccinations) Order 2021.

4 Schedule 3 replaced

Replace Schedule 3 with the Schedule 3 set out in the Schedule of this order.

Schedule Schedule 3 replaced

cl 4

Schedule 3 Vaccinations

cls 4, 9A

Item	Doses of COVID-19 vaccine	Administration requirements
1	2 doses of Pfizer/BioNTech (Comirnaty, Tozinameran, BNT162b2)	Either— (a) both doses received before carrying out certain work; or (b) 1 dose received before carrying out certain work and the second dose received within 35 days of having the first dose
2	2 doses of AstraZeneca (Oxford/AstraZeneca, Vaxzevria, AZD1222, ChAdOx1 nCoV-19)	Either— (a) both doses received before carrying out certain work; or (b) 1 dose received before carrying out certain work and the second dose received within 35 days of having the first dose
3	2 doses of AstraZeneca (Covishield, Serum Institute India formulation)	Both doses received before carrying out certain work
4	2 doses of Moderna (Spikevax, mRNA-1273)	Both doses received before carrying out certain work
5	2 doses of Sinopharm, Beijing (BBIBP-CorV, BIBP vaccine, Covilo)	Both doses received before carrying out certain work
6	2 doses of Sinovac (CoronaVac, PiCoVacc)	Both doses received before carrying out certain work
7	2 doses of Bharat Biotech (Covaxin, BBV152)	Both doses received before carrying out certain work
8	1 dose of Janssen / Johnson & Johnson (Janssen COVID-19 Vaccine, Ad26.COV2.S1, JNJ-78436735)	Dose received before carrying out certain work
9	2 doses of Novavax (Nuvaxovid, NVX-CoC2373)	Both doses received before carrying out certain work
10	2 doses of Covovax (Serum Institute India Novavax formulation)	Both doses received before carrying out certain work
11	2 doses of any combination of the following: Pfizer/BioNTech (Comirnaty, Tozinameran, BNT162b2): Moderna (Spikevax, mRNA-1273): AstraZeneca (Oxford/AstraZeneca, Vaxzevria, AZD1222, ChAdOx1 nCoV-19): AstraZeneca (Covishield, Serum Institute India formulation): Sinopharm, Beijing (BBIBP-CorV, BIBP vaccine, Covilo): Sinovac (CoronaVac, PiCoVacc): Bharat Biotech (Covaxin, BBV152): Novavax (Nuvaxovid, NVX-CoC2373): Covovax (Serum Institute India Novavax formulation)	Either— (a) both doses received before carrying out certain work; or (b) 1 dose received before carrying out certain work and the second dose received within 35 days of having the first dose
12	If a person has received 1 or more doses (or for Zydus Cadila or Rasi Cov Pars, 1, 2, or 3 doses) of any of the following, then 1 additional dose of Pfizer/BioNTech, Moderna, AstraZeneca (Vaxzevria or Covishield), or Janssen vaccine is required: Sinopharm, Wuhan (WIBP-CorV. Inactivated Vero Cells): Sputnik V (Gamaleya Research Institute of Epidemiology and Microbiology Gam-COVID-Vac): Gamaleya Research Institute of Epidemiology and Microbiology (Sputnik light): Takeda (TAK-919) (note: this is a Moderna formulation): CanSino (Convidecia, PakVac, Ad5-nCoV): Zydus Cadila (ZyCoV-D): Anhui Zhifei Longcom (Zifivax, ZF2001, ZF-UZ-VAC-2001): Minhai Biotechnology Co (Beijing) (KCONVAC, Minhai COVID-19 vaccine): Shifa Pharmed Industrial Co (COVIran Barekat, BIV1-CoVIran): Federal Budgetary Research Institution State Research Center of Virology and Biotechnology VECTOR FBRI (EpiVacCorona, Aurora-CoV): Chumakov Centre (KoviVac): Khazakstan Research Institute for Biological Safety Problems, RIBSP (QazVac, QazCovid-in): Medigen Vaccine Biologics Corporation, MVC (MVC COVID-19 vaccine, MVC-COV1901): Center for Genetic Engineering and Biotechnology, CIGB (Abdala, CIGB-66): Vaxine/CinnaGen Co COVAX-19 (SpikoGen): Biological E. (BioE) Limited (Corbevax, BECOV2D, BECOV2A, BioE COVID-19): Federal Budgetary Research Institution State Research Center of Virology and Biotechnology VECTOR, FBRI (EpiVacCorona-N, EpiVacCorona): Health Institutes of Turkey (Turkovac, ERUCOV-VAC): Instituto Finlay de Vacunas Cuba (Soberana 02, FINLAY-FR-2, Pasteurcovac): National Vaccine and Serum Institute, China (Recombinant SARS-COV-2 Vaccine (CHO Cell), NVSI-0608, Recombinant COVID-19 Vaccine (CHO cell, NVSI-06-08)): Organization of Defensive Innovation and Research, Iran (FAKHRAVAC, MIVAC): Razi Vaccine and Serum Research Institute, Iran (Rasi Cov Pars)	All doses must be received before carrying out certain work
13	If a person has received 2 doses of Instituto Finlay de Vacunas Cuba (Soberana 02, FINLAY-FR-2, Pasteurcovac) and 1 dose of Instituto Finlay de Vacunas Cuba (Soberana Plus, FINLAY-FR-1A), then 1 additional dose of Pfizer/BioNTech, Moderna, AstraZeneca (Vaxzevria or Covishield), or Janssen vaccine is required	All doses must be received before carrying out certain work

Dated at Wellington this 22nd day of March 2022.

Hon Chris Hipkins,
Minister for COVID-19 Response.

Explanatory note

This note is not part of the order, but is intended to indicate its general effect.

This order amends the COVID-19 Public Health Response (Vaccinations) Order 2021 (the principal order), which requires persons who belong to specified groups and carry out certain work (affected persons) to be vaccinated. This order comes into force at 11.59 pm on 25 March 2022.

This order replaces Schedule 3 of the principal order to—

update the names of some vaccines; and
set out an expanded range of vaccines, or combinations of vaccines, that an affected person may receive (in accordance with the specific requirements) to be recognised as vaccinated.

Approval by resolution required

This order must be approved by a resolution of the House of Representatives before the expiry of the period described in section 16(2) of the COVID-19 Public Health Response Act 2020. If that does not happen, the order is revoked on the expiry of that period.

Issued under the authority of the Legislation Act 2019.

Date of notification in Gazette: 23 March 2022.

Notes

1 General

This is a consolidation of the COVID-19 Public Health Response (Vaccinations) Amendment Order (No 3) 2022 that incorporates the amendments made to the legislation so that it shows the law as at its stated date.

2 Legal status

A consolidation is taken to correctly state, as at its stated date, the law enacted or made by the legislation consolidated and by the amendments. This presumption applies unless the contrary is shown.

Section 78 of the Legislation Act 2019 provides that this consolidation, published as an electronic version, is an official version. A printed version of legislation that is produced directly from this official electronic version is also an official version.

3 Editorial and format changes

The Parliamentary Counsel Office makes editorial and format changes to consolidations using the powers under subpart 2 of Part 3 of the Legislation Act 2019. See also PCO editorial conventions for consolidations.

4 Amendments incorporated in this consolidation

COVID-19 Public Health Response (Revocations) Order 2022 (SL 2022/254): clause 3(2)

COVID-19 Public Health Response (Vaccinations) Amendment Order (No 3) 2022